How to reconcile Carta equity records to your general ledger

Your cap table shows 1.4 million options vesting. Your books show zero stock-based compensation expense. Here is what that gap costs at Series A diligence.

A startup CFO we work with found out about the gap three weeks before closing a Series A. Investor counsel requested a stock-based compensation supporting schedule. The bookkeeper pulled the expense from QuickBooks: $0 over two years of operations. Carta showed 1.4 million options outstanding across six grants, four of which had been vesting for more than a year. The missing expense was $143,000. The company had been understating its operating costs for six consecutive quarters.

What the gap is and why it exists

Carta is an excellent tool for tracking equity events. It records every grant, exercise, cancellation, and cap table change with precision. It does not write journal entries.

The connection between what Carta tracks and what QuickBooks needs to show is manual. In most early-stage biotech companies, no one is making that connection on a regular schedule. The result is a gap that can accumulate for years before a financing round or audit brings it to the surface.

Four things that create the gap

Stock-based compensation not recorded. When a company grants stock options to employees, accounting standard ASC 718 requires recognizing the fair value of those options as compensation expense, spread over the vesting period. Most early-stage companies record the Carta grant and stop there. No monthly expense entry follows. After two years of vesting, the Profit and Loss report (P&L) understates operating expenses by the cumulative grant-date fair values of every active grant.

Option exercises recorded as income. When an employee pays the exercise price to acquire shares, the company receives cash. Many bookkeepers record that deposit as consulting revenue or miscellaneous income. It is neither. The exercise is an equity transaction. The cash goes to common stock at par value and additional paid-in capital (APIC), not to the income statement.

SAFE conversions left on the balance sheet. Simple Agreements for Future Equity (SAFEs) appear as liabilities until they convert. When a financing closes and a SAFE converts to shares, the liability should be reversed and moved to equity the same day. If no one is watching the cap table at closing, the SAFE balance can sit on the books for months after conversion, overstating liabilities and understating equity simultaneously.

Forfeitures not reversed. When an employee leaves and Carta cancels their unvested options, any previously recognized expense on those options should be reversed in QuickBooks. If no one reverses it, operating expenses remain overstated and equity accounts stay inflated.

What the books should have shown

A two-year-old preclinical startup had issued option grants to five employees. Here is what the financial statements reported versus what they should have reflected:

Line	Books reported	Should have shown
Stock-based compensation expense (cumulative)	$0	$143,000
Total operating expenses (two years)	$1,820,000	$1,963,000
Additional paid-in capital	$2,100,000	$2,243,000
Net loss (two years)	($1,820,000)	($1,963,000)

The company had been reporting a smaller operating loss than it was actually incurring. Correcting it required three weeks of reconstruction and a revised set of financial statements before the term sheet terms could be finalized.

Why this matters before it surfaces

The P&L misstates operating costs. Stock-based compensation is a real cost. Under generally accepted accounting principles (GAAP), it belongs on the P&L in the period employees earned it. Excluding it makes the company look less expensive to operate than it is. For a biotech managing runway carefully, that misstatement affects every planning decision tied to the expense line.

Audited financials take more time to produce. Any biotech planning a Series B or a large pharmaceutical partnership will eventually need audited financials. An audit that covers two or three years of missing stock-comp requires reconstructing every grant, recalculating every month of expense, and restating each prior period. That is billable time on top of the standard audit fee.

Cap table and equity section conflict in diligence. Investor counsel compares the cap table in Carta to the equity section of the balance sheet. When those numbers disagree, questions arise about whether the finance function is reliable. Those questions are hard to answer quickly during a live financing.

What a reliable reconciliation looks like

For life sciences clients we work with, the Carta-to-GL reconciliation runs on the same schedule as month-end close. Each month: export equity activity from Carta, calculate that month’s stock-based compensation by grant, post the journal entry, record any exercises or conversions that occurred during the period, and confirm that shares outstanding in the equity accounts match Carta.

The process takes one to two hours per month once a grant-tracking spreadsheet is in place. The spreadsheet holds the key terms for each grant: grant date, exercise price, vesting schedule, grant-date fair value from the 409A valuation report, and the resulting monthly expense. Adding a new grant takes ten minutes.

Best practices for biotech equity accounting

Set up a grant-tracking spreadsheet when each option grant is approved. Record the grant-date fair value from the current 409A, the vesting start date, and the vesting term in months. Monthly stock-based compensation flows from this spreadsheet into QuickBooks at every close.
Record stock-based compensation as a separate operating expense line item, not folded into payroll. Investors and auditors look for it on a standalone basis, and burying it inside payroll makes reconciliation harder.
Reconcile Carta shares outstanding to the equity section of the balance sheet every month, not only before a financing.
Zero out SAFE liabilities the day a round closes. Do not let a converted SAFE remain on the books as a liability after shares have been issued.
Keep the 409A valuation report with the grants it supports. The per-share fair value behind every monthly expense calculation should trace directly to a specific 409A report date.

Three questions worth asking

Does our bookkeeper calculate monthly stock-based compensation expense from a Carta grant schedule, or does the P&L show $0 in stock-comp across all periods?
When the last option exercise occurred, how was the cash recorded, and was a matching equity entry made in QuickBooks?
If we have outstanding SAFEs, where do they appear on the balance sheet today, and are any of them still there after a prior conversion?

If those answers come back uncertain, Carta and the books are not reconciled. Send us the last 12 months of financials alongside your Carta cap table, and we will identify what is missing and what it takes to bring the books current before your next financing.